<DOC>
	<DOCNO>NCT00420212</DOCNO>
	<brief_summary>To determine treatment BG00012 decrease number MS relapse certain time period . To determine , time , BG00012 treatment decrease number certain type brain lesion commonly see MS patient slow time take disease get bad . The purpose study also determine safety BG00012 well tolerate . Another goal see effect BG00012 may test evaluation use assess MS .</brief_summary>
	<brief_title>Efficacy Safety Oral BG00012 Relapsing-Remitting Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Dimethyl Fumarate</mesh_term>
	<criteria>Key Unless otherwise specify , eligible participate study , candidate must meet following eligibility criterion time randomization : Must confirm diagnosis RRMS accord McDonald criterion # 14 . Must baseline EDSS 0.0 5.0 , inclusive . Must relapsingremitting disease course . Key Unless otherwise specify , candidate exclude study entry follow exclusion criterion exist randomization : Other chronic disease immune system , malignancy , acute urologic , pulmonary , gastrointestinal disease . Pregnant nursing woman . Note : Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>relapse</keyword>
	<keyword>oral</keyword>
	<keyword>remit</keyword>
	<keyword>multiple sclerosis</keyword>
</DOC>